Editorial: Alzheimer’s disease

Keywords

Alzheimer’s disease / biomarkers / apolipoprotein E / neuroimaging / treatments / phenolic compounds / hydrophobic peptides / neurostimulation

References

[1] Yanai H,Adachi H,Hakoshima M,Katsuyama H.Pathology and Treatments of Alzheimer’s disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes.Molecules.2024;29:5936.

[2] Breijyeh Z,Karaman R.Comprehensive Review on Alzheimer’s disease: Causes and Treatment.Molecules.2020;25:5789.

[3] Alty J,Goldberg LR,Roccati E,Lawler K,Bai Q,Huang G,et al.Development of a smartphone screening test for preclinical Alzheimer’s disease and validation across the dementia continuum.BMC Neurol.2024;24:127.

[4] Collaborators G2CoD.Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Lancet.2024;403:2100-32.

[5] Colom-Cadena M,Spires-Jones T,Zetterberg H,Blennow K,Caggiano A,DeKosky ST,et al.Synaptic Health Endpoints Working Group.The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease.Alzheimers Res Ther.2020;12:21.

[6] Pluta R.A Look at the Etiology of Alzheimer’s disease based on the Brain Ischemia Model.Curr Alzheimer Res.2024;21:166-82.

[7] Castellani RJ,Jamshidi P,Plascencia-Villa G,Perry G.The Amyloid Cascade Hypothesis: A Conclusion in Search of Support.Am J Pathol.2024;S0002–944000407–3

[8] Błaszczyk JW.Sleep disorders contribute to the development of dementia and Alzheimer’s disease.Explor Neurosci.2023;2:212-23.

[9] Holston EC.Raw resting-state electroencephalogram biomarker emerges as an indicator of Alzheimer’s disease over a two-year period.Explor Neurosci.2025;4:100677.

[10] Yuri T,Degrieck R,Minczakiewicz D,Sato H,Kamada J,Nakazawa T,et al.Estimation of the allelic status of apolipoprotein E4 isoforms with fully automated LUMIPULSE^® assays.Explor Neurosci.2023;2:238-44.

[11] Mulumba J,Duan R,Luo B,Wu J,Sulaiman M,Wang F,et al.The role of neuroimaging in Alzheimer’s disease: implications for the diagnosis, monitoring disease progression, and treatment.Explor Neurosci.2025;4:100675.

[12] Xiao D,Zhang C.Current therapeutics for Alzheimer’s disease and clinical trials.Explor Neurosci.2024;3:255-71.

[13] Medeiros J.Phenolic compounds as anti-Alzheimer’s disease agents.Explor Neurosci.2025;4:100693.

[14] Gutierrez-Merino C.Anti-amyloid β hydrophobic peptides in Alzheimer’s disease: biomarkers and therapeutic potential.Explor Neurosci.2025;4:100672.

[15] Sengupta P,Das R,Majumder P,Mukhopadhyay D.Connecting the ends: signaling via receptor tyrosine kinases and cytoskeletal degradation in neurodegeneration.Explor Neurosci.2024;3:1-26.

[16] Perez FP,Walker B,Morisaki J,Kanakri H,Rizkalla M.Neurostimulation devices to treat Alzheimer’s disease.Explor Neurosci.2025;4:100674.